| Literature DB >> 28838420 |
Abstract
In patients with Crohn's disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti-drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn's disease on biologic medications.Entities:
Keywords: Anti-drug antibodies; Anti-tumor necrosis factor; Biologics; Crohn's disease; Drug concentrations; Inflammatory bowel disease; Therapeutic drug monitoring
Mesh:
Substances:
Year: 2017 PMID: 28838420 DOI: 10.1016/j.gtc.2017.05.014
Source DB: PubMed Journal: Gastroenterol Clin North Am ISSN: 0889-8553 Impact factor: 3.806